Nonclinical pharmacokinetics and absorption, distribution, metabolism, and excretion properties of MORF-057 support its clinical development as an oral selective α4β7 integrin inhibitor

被引:0
|
作者
Jones, J. [1 ]
Lee, D. [1 ]
Smukste, I. [1 ]
Cui, D. [1 ]
Bursavich, M. G. [2 ]
Troast, D. [2 ]
Zhong, C. [2 ]
Wong, J. E. [3 ]
Mangada, M. M. [3 ]
Bain, G. [3 ]
Lippa, B. [2 ]
Ray, A. S. [3 ]
Rogers, B. N. [4 ]
机构
[1] Morph Therapeut, Dmpk, Waltham, MA USA
[2] Morph Therapeut, Mol Discovery, Waltham, MA USA
[3] Morph Therapeut, Biol & Translat, Waltham, MA USA
[4] Morph Therapeut, Res, Waltham, MA USA
来源
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词
D O I
10.1093/ecco-jcc/jjab076.166
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
P037
引用
收藏
页码:S149 / S150
页数:3
相关论文
共 2 条
  • [1] Oral α4β7 integrin inhibitor MORF-057 demonstrates exposure driven biomarker response in non-human primates
    Wong, J.
    Lee, D.
    Mangada, M.
    Yadav, V.
    Troast, D.
    Zhong, C.
    Hahn, K.
    Wang, W.
    Ge, X.
    Sun, L.
    Jiang, S.
    Wang, B.
    Zhang, J.
    Yan, L.
    Nguyen, H.
    Cui, D.
    Bursavich, M. G.
    Lippa, B.
    Rogers, B. N.
    Ray, A. S.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I098 - I099
  • [2] MORF-057, an oral selective α4β7 integrin inhibitor for Inflammatory Bowel Disease, leads to specific target engagement in a single and multiple ascending dose study in healthy subjects
    Ray, A.
    Cui, D.
    Lee, D.
    Mangada, M. M.
    Jones, J.
    Bain, G.
    Traber, P. G.
    Vrishabhendra, L. H.
    Krzeski, P. W.
    Vande Casteele, N.
    Reardon, M. M.
    Stern, T. P.
    Soo, C. L.
    Nguyen, H.
    Rogers, B. N.
    Linde, P. G.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S333 - S335